PULM Pulmatrix Corporation: Long-Term Debt to Capital Coefficient

Symbol and logo of brand Pulmatrix Corporation (PULM)

Pulmatrix, Inc. (PULM) price action depends on the outcomes of the PUR1900 tests and the potential of the iSPERSE platform. The foundation is based on innovations in inhalation delivery, although the early stage of development creates binary risks. The long-term financial leverage ratio visualizes the dependence of borrowed funds on equity, with the latest parameter standing at 0.00, which determines the company's current debt sustainability.

PULM - Pulmatrix Inc Long-Term Debt to Equity over the range 07/04/2022 - 10/28/2026

Comprehensive metric breakdowns and analytics for Pulmatrix, Inc. (PULM)

- price and consensus price forecast:
Quote Chart Pulmatrix Inc|PULM - Analyst Consensus Forecast
- market capitalization data:
Market Value Pulmatrix, Inc.|PULM - Enterprise Value
- book capitalization data:
Book Value per Share Pulmatrix|PULM - Company Book Value|Market Value to Book Value pulmatrix.com|PULM - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Pulmatrix, Inc.|PULM - Long-Term Debt to Capital|Short-Term Debt to Capital pulmatrix.com|PULM - Company Total Debt|Debt to Net Assets Ratio Pulmatrix, Inc.|PULM - Company Long-Term Debt|Short-Term Debt Pulmatrix
Initial company analysis:Pulmatrix Inc
Core merchandise of Pulmatrix, Inc.

As Pulmatrix, Inc. (PULM) develops its innovative iSPERSE platform for the treatment of rare diseases, the company requires strategic financing. This long-term debt capital coverage ratio compares obligations with maturities exceeding one year against equity. An increase in this indicator signals higher financial leverage to accelerate commercialization, while declining values suggest a conservative approach to borrowing. This determines the company's resilience to market shocks.

Who Pulmatrix, Inc. competes with

Long-Term Liabilities to Equity Haleon PLC|Kenvue Corp (KVUE) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Verona Pharma Inc. (VRNA)|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|ligand.com - Long-Term Debt to Capital|Long-Term Debt to Equity Amneal (AMRX)|PRGO: Long-Term Debt to Capital Coefficient|ALVO (Alvotech Corp) - Long-Term Debt to Equity|Liquidia Inc. (LQDA) - Long-Term Debt to Equity Ratio|GLPG (Galapagos NV) - Long-Term Debt to Capital|Long-Term Debt to Capital anipharmaceuticals.com (ANIP)|MannKind (MNKD) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient AMPH (Amphastar Pharmaceuticals Inc)|PCRX: Long-Term Debt to Equity|SPRY - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Theravance Biopharma TBPH|AQST - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital scpharmaceuticals.com SCPH|Tectonic Therapeutic (TECX) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital TNXP (Tonix Pharmaceuticals Inc.)|Long-Term Liabilities to Capital SXTC|Eupraxia Pharmaceuticals (EPRX) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient BHST (bioharvest.com)|eXoZymes (EXOZ) - Long-Term Debt to Equity|ORMP - Long-Term Liabilities to Equity|Entera Bio Corp - Long-Term Debt to Equity Ratio|HYFT: Long-Term Debt to Capital|ABVC BioPharma (ABVC) - Long-Term Debt to Equity|CPIX (cumberlandpharma.com) - Long-Term Debt to Equity|Long-Term Debt to Equity QNTM|Long-Term Debt to Equity Ratio FibroGen Inc|Long-Term Debt to Capital TELO|Long-Term Debt to Capital ranitherapeutics.com RANI|Long-Term Debt to Equity Ratio Synergy CHC (SNYR)|Rallybio Corp - Long-Term Loans to Capital Ratio|Long-Term Debt to Equity Lexaria (LEXX)|PTHL - Long-Term Debt to Capital Coefficient|aptorumgroup.com - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Lyra Therapeutics Inc|Long-Term Debt to Equity Ratio Impact BioMedical Inc (IBO)|Long-Term Debt to Capital Ratio TNF Pharma (TNFA)|cbdMD, Inc. (YCBD) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient PainReform Ltd (PRFX)|Long-Term Debt to Capital CYTO|Lipella Pharma - Ratio of Long-Term Indebtedness to Capital|OptiNose, Inc. (OPTN) - Long-Term Debt to Equity|PIRS - Long-Term Debt to Capital Ratio|PROC (Procaps) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Petros Pharmaceuticals Inc|QLI: Long-Term Debt to Equity Ratio|Ratio of Long-Term Indebtedness to Capital SLRN|TFFP - Long-Term Debt to Equity